choline has been researched along with MELAS in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the utility of Magnetic Resonance Spectroscopy (MRS) as a biomarker of response to L-arginine in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS)." | 3.91 | MELAS: Monitoring treatment with magnetic resonance spectroscopy. ( Chong, RA; DeGiorgio, CM; Galati, A; Hovsepian, DA; Mazumder, R; Mishra, S; Yim, C, 2019) |
| " Mutation carriers included 45 patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS); 11 participants who would develop the MELAS syndrome during follow-up (converters); and 79 participants who would not develop the MELAS syndrome during follow-up (nonconverters)." | 3.80 | Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers. ( De Vivo, D; DiMauro, S; Engelstad, KM; Hinton, V; Kaufmann, P; Mao, X; Shungu, D; Weiduschat, N, 2014) |
| "Localized brain proton MR spectra were acquired from patients with different mitochondrial encephalomyopathies (myoclonus epilepsy with ragged-red fibers [MERRF], Kearns-Sayre syndrome [KSS], and mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS])." | 3.68 | Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies. ( Andermann, F; Arnold, DL; Karpati, G; Mathews, PM; Silver, K, 1993) |
| "Six patients with MELAS (age 28 ± 13 years, 3 [50%] female) and 17 with MSS (age 45 ± 11 years, 7 [41%] female) and 39 sex- and age-matched healthy controls (HC) were enrolled." | 1.62 | Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations. ( Amore, G; Bianchini, C; Caporali, L; Carelli, V; Cortesi, I; Di Vito, L; Evangelisti, S; Gramegna, LL; La Morgia, C; Liguori, R; Lodi, R; Manners, DN; Maresca, A; Talozzi, L; Testa, C; Tonon, C; Valentino, ML, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gramegna, LL | 1 |
| Evangelisti, S | 1 |
| Di Vito, L | 1 |
| La Morgia, C | 1 |
| Maresca, A | 1 |
| Caporali, L | 1 |
| Amore, G | 1 |
| Talozzi, L | 1 |
| Bianchini, C | 1 |
| Testa, C | 1 |
| Manners, DN | 1 |
| Cortesi, I | 1 |
| Valentino, ML | 1 |
| Liguori, R | 1 |
| Carelli, V | 1 |
| Tonon, C | 1 |
| Lodi, R | 1 |
| Wang, R | 1 |
| Hu, B | 1 |
| Sun, C | 1 |
| Geng, D | 1 |
| Lin, J | 1 |
| Li, Y | 1 |
| Hovsepian, DA | 1 |
| Galati, A | 1 |
| Chong, RA | 1 |
| Mazumder, R | 1 |
| DeGiorgio, CM | 1 |
| Mishra, S | 1 |
| Yim, C | 1 |
| Weiduschat, N | 1 |
| Kaufmann, P | 1 |
| Mao, X | 1 |
| Engelstad, KM | 1 |
| Hinton, V | 1 |
| DiMauro, S | 1 |
| De Vivo, D | 1 |
| Shungu, D | 1 |
| Liu, Z | 1 |
| Zheng, D | 1 |
| Wang, X | 1 |
| Zhang, J | 1 |
| Xie, S | 1 |
| Xiao, J | 1 |
| Jiang, X | 1 |
| Mathews, PM | 1 |
| Andermann, F | 1 |
| Silver, K | 1 |
| Karpati, G | 1 |
| Arnold, DL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mitochondrial Encephalomyopathies and Mental Retardation: Investigations of Clinical Syndromes Associated With MtDNA Point Mutations[NCT01532791] | 300 participants (Anticipated) | Observational | 2004-07-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 other studies available for choline and MELAS
| Article | Year |
|---|---|
Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Biomarkers; Cerebellum; Cerebral Cortex; Choline; DNA, Mitoc | 2021 |
Metabolic abnormality in acute stroke-like lesion and its relationship with focal cerebral blood flow in patients with MELAS: Evidence from proton MR spectroscopy and arterial spin labeling.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Case-Control Studies; Choline; Creatine; Female; Glutamic A | 2021 |
MELAS: Monitoring treatment with magnetic resonance spectroscopy.
Topics: Arginine; Aspartic Acid; Brain; Choline; Female; Humans; Magnetic Resonance Spectroscopy; MELAS Synd | 2019 |
Cerebral metabolic abnormalities in A3243G mitochondrial DNA mutation carriers.
Topics: Acidosis, Lactic; Adult; Aged; Aspartic Acid; Cerebral Cortex; Choline; Creatine; DNA, Mitochondrial | 2014 |
Apparent diffusion coefficients of metabolites in patients with MELAS using diffusion-weighted MR spectroscopy.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Child; Choline; Creatinine; Diffusion; Female; Humans; Magn | 2011 |
Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies.
Topics: Aspartic Acid; Brain; Choline; Creatine; Humans; Kearns-Sayre Syndrome; Lactates; Lactic Acid; Magne | 1993 |